Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-07-28 09:01 am Purchase |
2023-07-19 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Polar Capital Holdings Plc | 157,448 5.020% |
157,448 (New Position) |
Filing History |
| 2023-07-18 4:01 pm Purchase |
2023-07-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Logos Global Management LP | 254,000 8.100% |
254,000 (New Position) |
Filing History |
| 2023-07-10 4:16 pm Purchase |
2023-06-28 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Venrock Healthcare Capital Partners III L.P. | 319,200 9.990% |
319,200 (New Position) |
Filing History |
| 2023-07-03 4:20 pm Purchase |
2023-06-22 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Affinity Healthcare Fund, LP | 299,080 9.230% |
299,080 (New Position) |
Filing History |
| 2023-06-30 5:24 pm Purchase |
2023-06-22 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Fairmount Funds Management LLC | 783,600 19.990% |
783,600 (New Position) |
Filing History |
| 2023-06-30 4:20 pm Purchase |
2023-06-22 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
EcoR1 Capital Fund Qualified L.P. | 200,000 6.400% |
200,000 (New Position) |
Filing History |
| 2023-06-30 4:00 pm Purchase |
2023-06-22 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Deep Track Capital, LP | 290,322 9.990% |
290,322 (New Position) |
Filing History |
| 2023-02-14 4:55 pm Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Nantahala Capital Management, LLC | 184,452 7.500% |
71,910 (+63.90%) |
Filing History |
| 2023-02-14 4:01 pm Sale |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ORBIMED ADVISORS LLC | 71,889 2.900% |
-86,356 (-54.57%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 255,361 9.900% |
53,581 (+26.55%) |
Filing History |
| 2023-02-14 2:51 pm Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Rock Springs Capital Management LP | 136,556 5.550% |
136,556 (New Position) |
Filing History |
| 2023-02-14 06:04 am Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BCLS II Equity Opportunities LP | 213,908 8.700% |
100,000 (+87.79%) |
Filing History |
| 2023-02-13 08:41 am Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
SUVRETTA CAPITAL MANAGEMENT, LLC | 255,055 9.990% |
152,215 (+148.01%) |
Filing History |
| 2023-02-03 11:43 am Sale |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
PICTET ASSET MANAGEMENT SA | 0 0.000% |
-100,773 (Position Closed) |
Filing History |
| 2023-01-10 4:36 pm Sale |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Integrated Core Strategies (US) LLC | 125,259 5.100% |
-6,372 (-4.84%) |
Filing History |
| 2022-12-01 4:07 pm Purchase |
2022-11-23 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Integrated Core Strategies (US) LLC | 131,631 5.300% |
131,631 (New Position) |
Filing History |
| 2022-06-09 3:20 pm Sale |
2022-05-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BlackRock Inc. BLK |
117,707 4.800% |
-2,233 (-1.86%) |
Filing History |
| 2022-02-14 4:25 pm Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Point72 Asset Management, L.P. | 2,244 0.100% |
-114,948 (-98.09%) |
Filing History |
| 2022-02-14 08:01 am Purchase |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Nantahala Capital Management, LLC | 112,542 5.700% |
15,982 (+16.55%) |
Filing History |
| 2022-02-14 06:40 am Purchase |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BCLS II Equity Opportunities LP | 113,908 5.800% |
5,908 (+5.47%) |
Filing History |